IP Library Granted Patent US 7,968,316
Granted Patent B2
US 7,968,316 · App. 12/063,379 · Granted Jun 28, 2011

Method for the mass production of immunoglobulin Fc region deleted initial methionine residues

Assignee: Hanmi Holdings Co., Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,968,316
App. No.
12/063,379
Granted
Jun 28, 2011
Kind
B2
Abstract

Disclosed is a method for the mass production of a monomeric or dimeric immunoglobulin Fc region, free of initial methionine residues, using a recombinant expression vector comprising a nucleotide sequence coding for a recombinant immunoglobulin Fc region comprising an immunoglobulin Fc region linked at the N-terminus thereof to an immunoglobulin Fc region via a peptide bond.

Claims (20)

1. A method of producing an immunoglobulin Fc region free of an initial methionine residue, comprising:

preparing a recombinant expression vector including a nucleotide sequence coding for a recombinant immunoglobulin Fc region composed of an immunoglobulin Fc region linked at the N-terminus thereof to an immunoglobulin hinge region via a peptide bond;

transforming a prokaryotic cell with the recombinant expression vector to create a transformant;

culturing the transformant to express the immunoglobulin Fc region as an inclusion body; and

isolating the immunoglobulin Fc region,

wherein the immunoglobulin hinge region has cysteine, serine or proline as an initial amino acid of the N-terminus.

2. The method according to claim 1 , wherein the immunoglobulin Fc region is isolated in a monomeric or dimeric form.

3. The method according to claim 1 , wherein the hinge region has two or more consecutive amino acid sequences derived from the hinge region of IgG, IgA, IgM, IgE, or IgD.

4. The method according to claim 3 , wherein the hinge region has two or more consecutive amino acid sequences, each including at least one cystein residue.

5. The method according to claim 3 , wherein the IgG is selected from the group consisting of IgG1, IgG2, IgG3 and IgG4.

6. The method according to claim 5 , wherein the hinge region has an amino acid sequence selected from the group consisting of SEQ ID NO. 18, 19, 20, 21, 49, 51, 53, 54, 55, 56, 57, 58, 59 and 60.

7. The method according to claim 1 , wherein the immunoglobulin Fc region is selected from the group consisting of Fc regions from IgG, IgA, IgM, IgE, IgD, and combinations and hybrids thereof.

8. The method according to claim 7 , wherein the immunoglobulin Fc region is the Fc region of the IgG selected from the group consisting of IgG1, IgG2, IgG3, IgG4, and combinations and hybrids thereof.

9. The method according to claim 1 , wherein the immunoglobulin Fc region is composed of one to four domains selected from the group consisting of CH1, CH2, CH3, CH4 and CL domains.

10. The method according to claim 1 , wherein the recombinant immunoglobulin Fc region has an amino acid sequence selected from the group consisting of SEQ ID NO. 7, 9, 11, 13, 25, 29, 31, 33, 35, 37, 39, 41, 43, 45, and 47.

11. The method according to claim 1 , wherein the recombinant expression vector includes a nucleotide sequence encoding an amino acid sequence selected from the group consisting of SEQ ID NO. 7, 9, 11, 13, 25, 29, 31, 33, 35, 37, 39, 41, 43, 45 and 47.

12. The method according to claim 1 , wherein the prokaryotic cell is E. coli.

13. The method according to claim 1 , wherein the transformant is transformed with a recombinant expression vector including a nucleotide sequence encoding an amino acid sequence selected from the group consisting of SEQ ID NO. 7, 9, 11, 13, 25, 29, 31, 33, 35, 37, 39, 41, 43, 45 and 47.

14. A monomeric or dimeric immunoglobulin Fc region free of initial methionine residues, prepared by the method of claim 1 .

15. The method according to claim 13 , wherein the transformant is selected from the group consisting of the transformants deposited under Accession Nos. KCCM-10659P, KCCM-10660P, KCCM-10665P and KCCM-10666P.

Assignments (4)
CHANGE OF NAME Recorded Aug 3, 2012
From: HANMI HOLDINGS CO., LTD.
To: HANMI SCIENCE CO., LTD.
Reel/Frame 028722/0341 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 5, 2011
From: HANMI PHARMACEUTICAL CO., LTD.
To: HANMI HOLDINGS CO., LTD.
Reel/Frame 025588/0197 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 30, 2010
From: JUNG, SUNG YOUB; KIM, JIN SUN; SHIN, JIN HWAN; KWON, SE-CHANG; LEE, GWAN-SUN; SONG, DAE HAE
To: HANMI PHARMACEUTICAL CO., LTD.
Reel/Frame 024765/0178 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 17, 2008
From: JUNG, SUNG YOUB; KIM, JIN SUN; SHIN, JIN HWAN; KWON, SE-CHANG; LEE, GWAN-SUN; SONG, DAE HAE
To: HANMI PHARMACEUTICAL CO., LTD.
Reel/Frame 021103/0387 →
Priority Claims (1)
KR 10-2005-0074989 · Aug 16, 2005 · national
Continuity (1)
Related Publication 20080293106A1 · Nov 27, 2008